Evidence map›Paper›PMID 34902236›Full record

ArticleThe Korean journal of internal medicine2022

Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide.

Seom Gim Kong, Je-Hwan Lee, Young Tak Lim, Ji Hyun Lee, Hyeon-Seok Eom, Hyewon Lee, Do Young Kim, Sung-Nam Lim, Sung-Soo Yoon, Sung-Yong Kim and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Seom Gim KongDepartment of Pediatrics, Kosin University College of Medicine, Busan, Korea.
Je-Hwan LeeDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Young Tak LimDepartment of Pediatrics, Pusan National University School of Medicine, Yangsan, Korea.
Ji Hyun LeeDepartment of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Korea.
Hyeon-Seok EomDepartment of Internal Medicine, National Cancer Center, Goyang, Korea.
Hyewon LeeDepartment of Internal Medicine, National Cancer Center, Goyang, Korea.
Do Young KimDepartment of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Sung-Nam LimDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea.
Sung-Soo YoonDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Sung-Yong KimDepartment of Internal Medicine, Konkuk University Medical Center, Seoul, Korea.
Ho Sup LeeDepartment of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
National Cancer Center · KRUlsan College · KRInje University Haeundae Paik Hospital · KRKonkuk University Medical Center · KRKosin University · KRPusan National University · KRPusan National University Hospital · KRSeoul National University Hospital · KR

Funding

Handok Inc., Seoul, Republic of Korea
6 · The paper itself

Abstract

BACKGROUND/

aimsVeno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is one of the most fatal complications of hematopoietic cell transplantation (HCT), and defibrotide is the only curative drug. We conducted this study to confirm the survival rate of VOD/SOS patients diagnosed in Korea and assess the efficacy of defibrotide.

methodsPatients diagnosed with VOD/SOS after allogenic HCT between 2003 and 2020 were enrolled. We investigated day +100 survival rates and associated risk factors in patients who satisfied the modified Seattle criteria within 50 days of HCT.

resultsA total of 110 patients satisfied the modified Seattle criteria, of which 65.5% satisfied the Baltimore criteria. Thirty-seven patients were treated with defibrotide. The day +100 survival rate of the 110 patients was 65.3%. The survival rates in patients who did not meet the Baltimore criteria and in those who did were 86.8% and 53.7%, respectively (p = 0.001). The day +100 survival rate of patients treated with defibrotide was 50.5%. Among the patients receiving defibrotide, those whose creatinine levels were more than 1.2 times the baseline had a significantly lower survival rate at 26.7% (p = 0.014). On multivariate regression analysis, the hazard ratio of satisfaction of the Baltimore criteria was 4.54 (95% confidence interval [CI], 1.69 to 12.21; p = 0.003). In patients treated with defibrotide, the hazard ratio was 8.70 (95% CI, 2.26 to 33.45; p = 0.002), when creatinine was more than 1.2 times the baseline on administration.

conclusionThe day +100 survival rate was significantly lower when the Baltimore criteria were satisfied, and when there was an increase in creatinine at the time of defibrotide administration.

Indexed as

Hematopoietic Stem Cell TransplantationHepatic Veno-Occlusive DiseaseCreatinineHumansPolydeoxyribonucleotidesCreatininedefibrotidePolydeoxyribonucleotidesCreatinineHematopoietic stem cell transplantationHepatic veno-occlusive diseaseRisk factorsSurvival rate

Identifiers

PMID34902236
PMCPMC8747908
OpenAlexW4200580856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.